Reducing Dementia Risk With Digital Health Coaching

NCT ID: NCT04559789

Last Updated: 2021-08-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-04

Study Completion Date

2024-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Digital Cognitive Multi-domain Alzheimer's Risk Velocity (DC MARVEL) study is a 2-year randomized controlled trial on dementia prevention. The purpose of this study is to determine the effect of a digital cognitive health program on dementia risk, cognitive function, and general health outcomes in middle age to older adults compared to a control group that receives health education.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Alzheimer's Disease (AD) is expected to affect 131 million people worldwide by 2050, but as many as 40% of these cases may be prevented by targeting modifiable risk factors such as diet, physical activity, cognitive engagement, and smoking. Neurotrack Technologies, Inc. will test the efficacy of a digital multi-domain lifestyle intervention with health coaching for cognitive health designed to change behaviors associated with increased risk for AD. This digital intervention addresses the challenge of scaling effective multi-domain lifestyle interventions for cognitive health and has the potential to improve risk behaviors, thereby reducing and/or delaying cognitive decline in older adults at risk for AD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease Dementia Mild Cognitive Impairment Cognitive Decline

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants are randomly allocated to either the intervention or control group at the beginning of the study
Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Investigators Outcome Assessors
All study investigators that collect or analyze data are blinded to the group assignment for all participants.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Digital Lifestyle Intervention

Participants randomized to the intervention arm will receive access to a digital intervention consisting of the MindMate cognitive health app and Neurotrack's personalized health coaching platform.

Group Type EXPERIMENTAL

MindMate + Health Coaching

Intervention Type BEHAVIORAL

The MindMate app is a digital multi-domain lifestyle intervention designed to address modifiable risk factors for dementia. The app will be augmented with digital health coaching provided by Neurotrack.

Health Education

Participants randomized to the control arm will receive digital health education materials that mirror the content in the app.

Group Type ACTIVE_COMPARATOR

Health Education

Intervention Type OTHER

Health education materials delivered electronically

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MindMate + Health Coaching

The MindMate app is a digital multi-domain lifestyle intervention designed to address modifiable risk factors for dementia. The app will be augmented with digital health coaching provided by Neurotrack.

Intervention Type BEHAVIORAL

Health Education

Health education materials delivered electronically

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 45-75
* BMI 18.5 - 39.9 kg/m2
* Fluent in English (written and spoken)
* A minimum of 2 of the following risk factors for AD from ANU-ADRI: High school education or less; Overweight, or class I or class II obese (BMI 25-39.9 kg/m2); History of diabetes; History of hypertension; History of high cholesterol; History of smoking; History of traumatic brain injury
* Maximum of 1 of the following protective factors for AD from ANU-ADRI: High level of physical activity; High fish consumption; High level of cognitive engagement
* Ability to send and receive text messages
* Own a smartphone, have a reliable internet connection, and willing to use email
* Ability to participate in light to moderate physical activity
* Willingness to be randomized

Exclusion Criteria

* Physician diagnosis of: mental health condition (e.g., eating disorder, alcohol/substance use, schizophrenia, etc.); neurologic conditions (e.g. epilepsy, stroke, multiple sclerosis, Parkinson's disease, brain tumor, or severe traumatic brain injury); dementia, probable dementia, or mild cognitive impairment; other significant health condition (e.g. congestive heart failure, chronic obstructive pulmonary disease, coronary artery disease, renal failure, chronic kidney disease, pulmonary hypertension)
* Recent cardiovascular event or recent treatment for cancer (within the last year); on dialysis; or on active organ transplant list
* Visual problems that prevent viewing screen at a normal distance (e.g., legal blindness, detached retina, occlusive cataracts)
* History of learning disability
* Currently participating in a formal cognitive training coaching program or other lifestyle change program (e.g. diabetes prevention program)
* Currently pregnant or planning on becoming pregnant in the next two years
Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Aging (NIA)

NIH

Sponsor Role collaborator

University of Arkansas

OTHER

Sponsor Role collaborator

Neurotrack Technologies, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jordan Glenn, PhD

Role: PRINCIPAL_INVESTIGATOR

Neurotrack Technologies, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Arkansas

Fayetteville, Arkansas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Myers JR, Bryk KN, Madero EN, McFarlane J, Campitelli A, Gills J, Jones M, Paulson S, Gray M, Glenn JM. Initial Perspectives From Rural-Residing Adults on a Digital Cognitive Health Coaching Intervention: Exploratory Qualitative Analysis. JMIR Form Res. 2024 Jul 22;8:e51400. doi: 10.2196/51400.

Reference Type DERIVED
PMID: 39038282 (View on PubMed)

Campitelli A, Paulson S, Gills JL, Jones MD, Madero EN, Myers J, Glenn JM, Gray M. A Novel Digital Digit-Symbol Substitution Test Measuring Processing Speed in Adults At Risk for Alzheimer Disease: Validation Study. JMIR Aging. 2023 Jan 27;6:e36663. doi: 10.2196/36663.

Reference Type DERIVED
PMID: 36705951 (View on PubMed)

Gray M, Madero EN, Gills JL, Paulson S, Jones MD, Campitelli A, Myers J, Bott NT, Glenn JM. Intervention for a Digital, Cognitive, Multi-Domain Alzheimer Risk Velocity Study: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2022 Feb 4;11(2):e31841. doi: 10.2196/31841.

Reference Type DERIVED
PMID: 35119374 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R44AG063672

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1R44AG063672-01

Identifier Type: NIH

Identifier Source: org_study_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.